Technical Analysis for SMMT - Summit Therapeutics plc

Grade Last Price % Change Price Change
grade D 1.93 -4.87% -0.10
SMMT closed down 4.87 percent on Monday, March 18, 2019, on 14 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Down
See historical SMMT trend table...

Date Alert Name Type % Chg
Mar 18 NR7 Range Contraction 0.00%
Mar 18 Inside Day Range Contraction 0.00%
Mar 18 Wide Bands Range Expansion 0.00%
Mar 15 Wide Bands Range Expansion -4.87%
Mar 14 Wide Bands Range Expansion -8.10%
Mar 13 MACD Bearish Signal Line Cross Bearish -2.04%
Mar 13 1,2,3 Pullback Bullish Bullish Swing Setup -2.04%
Mar 13 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -2.04%
Mar 13 Inside Day Range Contraction -2.04%
Mar 13 Wide Bands Range Expansion -2.04%

Older signals for SMMT ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Summit Corporation plc, a drug discovery and development company, engages in the discovery and development of novel drug candidates to treat areas of high unmet medical need. The company licenses its drug discovery platform, known as Seglin technology, for the identification of new drug leads and candidates with the potential to target a range of diseases. Its pipeline consists of clinical stage programmes targeting Duchenne Muscular Dystrophy (DMD) and Clostridium difficile infection (CDI). The company provides SMT C1100, a small molecule Utrophin modulator for DMD patients that has completed Phase I clinical trial; and SMT 19969, a Phase I clinical trial completed novel molecule antibiotic for the treatment for initial CDI and prevention of recurrent disease. It is also engaged in other programmes that include OGA inhibitor programme for the treatment of dementia. The company has a technology license agreement with Bristol-Myers Squibb to access the Seglin technology platform. It has operations primarily in the United Kingdom and the United States. The company was formerly known as VASTox plc and changed its name to Summit Corporation Plc in July 2007. Summit Corporation plc was founded in 2003 and is headquartered in Abingdon, the United Kingdom.
Medicine Medical Specialties Diseases Drug Discovery Dementia Muscular Dystrophy Duchenne Muscular Dystrophy Clostridioides Difficile Clostridium Difficile Infection
Is SMMT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 14.29
52 Week Low 1.1
Average Volume 78,623
200-Day Moving Average 2.9521
50-Day Moving Average 1.6194
20-Day Moving Average 1.9065
10-Day Moving Average 2.0589
Average True Range 0.1763
ADX 36.82
+DI 23.7154
-DI 14.8079
Chandelier Exit (Long, 3 ATRs ) 1.9311
Chandelier Exit (Short, 3 ATRs ) 1.7389
Upper Bollinger Band 2.6023
Lower Bollinger Band 1.2107
Percent B (%b) 0.52
BandWidth 72.992394
MACD Line 0.1392
MACD Signal Line 0.1634
MACD Histogram -0.0243
Fundamentals Value
Market Cap 23.9 Million
Num Shares 12.4 Million
EPS -0.36
Price-to-Earnings (P/E) Ratio -5.36
Price-to-Sales 4.01
Price-to-Book 26.16
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.10
Resistance 3 (R3) 2.12 2.08 2.07
Resistance 2 (R2) 2.08 2.04 2.07 2.06
Resistance 1 (R1) 2.00 2.01 1.98 1.99 2.05
Pivot Point 1.96 1.96 1.95 1.96 1.96
Support 1 (S1) 1.89 1.92 1.87 1.87 1.81
Support 2 (S2) 1.85 1.89 1.84 1.80
Support 3 (S3) 1.78 1.85 1.79
Support 4 (S4) 1.76